Atrys Health Stock

Atrys Health Financial Leverage

The Financial Leverage (Equity Multiplier) of Atrys Health (ATRY.MC) as of Aug 6, 2026 is 3.25. In the previous year, Financial Leverage (Equity Multiplier) was 2.31 — a change of 40.95% (higher).

Financial Leverage

3.25

YoY

40.95%

Last updated:

Financial Leverage (Equity Multiplier) of Atrys Health is 2026 3.25 . Financial Leverage (Equity Multiplier) of Atrys Health was 2025 2.31 . It decreases by 40.95% higher compared to the previous year.
Access this data via the Eulerpool API

Atrys Health Stock analysis

What does Atrys Health do? Atrys Health SA is a leading provider of medical services, founded in 2007 in Madrid, Spain, as a spin-off company of the Clinica Universidad de Navarra. The company's goal is to connect the limitless world of science and technology with the human component of healthcare. The business model of Atrys Health specializes in the development of products, services, and solutions in the field of medical imaging and cancer treatment. The company offers innovative technologies and medical services to help diagnose and treat patients better. Atrys Health consists of different business divisions focusing on the needs of clinical practice, research and development, and biotechnological production. The company aims to improve the efficiency and effectiveness of diagnosis, imaging, and treatment technologies to maximize results. The divisions of Atrys Health focus on various aspects of healthcare, including telemedicine, radiology, and proton therapy. Telemedicine provides a platform for remote treatments and medical consultation, improving access to specialists and enabling fast and effective diagnosis and treatment. The radiology division operates diagnostic centers specializing in medical imaging, equipped with the latest imaging technologies. The proton therapy division operates a proton therapy center in Madrid, offering advanced cancer treatment. Atrys Health offers a range of products tailored to the needs of clinical practice, research and development, and biotechnological production. Their key products include Atrilab, a leading platform for precision oncology diagnostics, Auriculum, a technology for precise radiation in cancer treatments, and Vida Oncology, a software solution for cancer treatment management. In conclusion, Atrys Health is a key player in medical imaging and cancer treatment, improving healthcare globally with advanced technologies and services. With their vision of combining innovative technologies with the human component of healthcare, Atrys Health will continue to lead in the healthcare industry. Atrys Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Atrys Health stock

Financial Leverage (Equity Multiplier) of Atrys Health is 3.25 in 2026.

Financial Leverage (Equity Multiplier) of Atrys Health changed from 2.31 to 3.25, representing a 40.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Atrys Health since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Atrys Health with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Atrys Health

All Key Metrics — Atrys Health